Press Releases

Company press releases and official corporate announcements.

A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.

Articles

10,273 total articles

USA Rare Earth Completes First Commercial Yttrium Metal Production

USA Rare Earth Completes First Commercial Yttrium Metal Production

USA Rare Earth, Inc., through its subsidiary Less Common Metals Ltd., has successfully completed the first commercial production of high-purity yttrium metal. This achievement establishes the company as one of the few non-Chinese producers of commercial-grade yttrium metal, critical for aerospace, defense, and advanced manufacturing sectors. The co…

Cibus Announces the Election of Thomas Urban to Board of Directors

Cibus Announces the Election of Thomas Urban to Board of Directors

Cibus, Inc., an agricultural technology company specializing in gene editing for crop traits, announced the election of Thomas Urban to its Board of Directors. Urban brings extensive agribusiness experience and is expected to support Cibus's commercialization initiatives and strategic growth plans. The company focuses on licensing its proprietary p…

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Tonix Pharmaceuticals Announces Publication of Steady-State Pharmacokinetics of TONMYA® After 20 Days of Daily Dosing in the Peer-Reviewed Journal, Clinical Pharmacology in Drug Development

Tonix Pharmaceuticals announced the publication of pharmacokinetic data for TONMYA® (cyclobenzaprine HCl sublingual tablets) after 20 days of dosing, supporting its FDA-approved regimen for fibromyalgia treatment. The study highlights TONMYA’s rapid absorption, improved bioavailability, and favorable safety profile, reinforcing the drug's potential…

Energous Reports Continued Commercial Momentum, Expanding Fortune 10 Deployments, and a Growing Multi-Vertical Proof-of-Concept Pipeline

Energous Reports Continued Commercial Momentum, Expanding Fortune 10 Deployments, and a Growing Multi-Vertical Proof-of-Concept Pipeline

Energous Corporation reported sustained commercial momentum entering 2026, highlighting expanding deployments with two Fortune 10 customers including international expansion, and a growing pipeline of proof-of-concept initiatives across retail, manufacturing, foodservice, and government sectors. The company also announced increased domestic manufac…

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis Announces Definitive Agreement to Acquire Robocath

Stereotaxis, a NYSE-listed leader in surgical robotics, entered into a definitive agreement to acquire Robocath, a French innovator in robotic technologies for interventional cardiology and neurointerventions. The acquisition aims to combine complementary robotic technologies to provide an integrated platform for a broad range of endovascular proce…

Dime Announces Appointment of Meyer Eichler as Executive Vice President, Managing Executive Director

Dime Announces Appointment of Meyer Eichler as Executive Vice President, Managing Executive Director

Dime Community Bancshares, a New York-based bank holding company, announced the appointment of Meyer Eichler as Executive Vice President and Managing Executive Director. Eichler will focus on expanding Dime's presence within the Orthodox Jewish community in New York and New Jersey, targeting key sectors such as healthcare, real estate, retail, whol…

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma to Present New Teverelix Data at AACE 2026 Demonstrating Long-Acting Hormone Suppression

Medicus Pharma announced new Phase 1 clinical data for Teverelix, its investigational long-acting GnRH antagonist, demonstrating predictable estradiol suppression, favorable pharmacokinetics for infrequent dosing, and good safety profile. The findings support advancing Teverelix development for hormone-driven conditions including endometriosis and …

Bitdeer Announces March 2026 Production and Operations Update

Bitdeer Announces March 2026 Production and Operations Update

Bitdeer Technologies Group announced significant operational growth in March 2026, including a 480% year-over-year increase in Bitcoin production to 661 BTC and a 105% month-over-month rise in AI cloud annual recurring revenue to approximately $43 million. The company is expanding its AI and Bitcoin mining infrastructure, advancing new colocation d…

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics Announces Completion of Enrollment for the Phase 3 Trial Evaluating Subcutaneous BRIUMVI

TG Therapeutics announced the completion of enrollment for its Phase 3 trial testing subcutaneous delivery of BRIUMVI, an anti-CD20 monoclonal antibody for relapsing multiple sclerosis (RMS). The study compares two dosing regimens administered subcutaneously to the existing intravenous formulation, aiming to demonstrate non-inferiority in drug expo…

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

Arbutus Biopharma announced that the U.S. FDA has granted Fast Track designation for their RNAi therapeutic imdusiran targeting chronic hepatitis B. This designation may accelerate the drug’s review and development, offering potential benefits such as earlier FDA interactions and expedited approval pathways. Clinical trials showed promising results…

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Plus Therapeutics Appoints Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR to Advance Market Access and Commercial Execution

Plus Therapeutics, a clinical-stage healthcare company specializing in precision diagnostics and radiopharmaceuticals for CNS cancers, has appointed Randy H. Goodman, PhD, MHA, as Vice President of Value Strategy & HEOR. Goodman brings over 20 years of experience in health economics, market access, and payer engagement, expected to fortify Plus The…

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy

Alterity Therapeutics announced a virtual event featuring key opinion leaders to discuss insights on their lead drug candidate ATH434 for Multiple System Atrophy (MSA). The company will review Phase 2 clinical trial results demonstrating clinical efficacy and provide a high-level overview of the planned Phase 3 pivotal trial. The event aims to info…

Monarch Casino & Resort, Inc. Slot Machine Change Program Surpasses $1 Million in Charitable Donations

Monarch Casino & Resort, Inc. Slot Machine Change Program Surpasses $1 Million in Charitable Donations

Monarch Casino & Resort, Inc. announced that its slot machine change donation program at Atlantis Casino Resort Spa in Reno and Monarch Casino Resort Spa Black Hawk has exceeded $1 million in contributions to various charities. Powered by IGT technology, the program allows guests to easily donate their remaining slot machine change to nonprofit org…

Traws Pharma Announces Up to $60 Million Private Placement Financing

Traws Pharma Announces Up to $60 Million Private Placement Financing

Traws Pharma announced a private placement financing expected to raise approximately $10 million in gross proceeds initially, with potential additional proceeds up to $50 million through milestone-based and three-year warrants. The financing will support the completion of a human challenge trial for its influenza treatment tivoxavir marboxil in the…

Union Bankshares Announces Earnings for the three months ended March 31, 2026 and Declares Quarterly Dividend

Union Bankshares Announces Earnings for the three months ended March 31, 2026 and Declares Quarterly Dividend

Union Bankshares, Inc. announced a net income increase to $3.0 million ($0.65 per share) for Q1 2026, driven by growth in net interest income and strong asset management. The bank's total assets rose by 6.6% year-over-year to $1.63 billion, with strategic investment securities growth. The company declared a $0.36 per share quarterly dividend, refle…

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

60 Degrees Pharmaceuticals announced that its FDA-approved malaria prevention drug ARAKODA (tafenoquine) is now available for purchase through the Runway Health telehealth platform, enabling U.S. travelers to conveniently obtain prescriptions and receive medication delivered prior to traveling to malaria-endemic regions. The once-weekly dosing regi…

Capital Clean Energy Carriers Corp. Divests 49% Stake in LNG Carrier ("LNG/C") Amore Mio I, Forms a Joint Venture Company With an Affiliate of the BGN Group and Secures 10-Year Time Charter

Capital Clean Energy Carriers Corp. Divests 49% Stake in LNG Carrier ("LNG/C") Amore Mio I, Forms a Joint Venture Company With an Affiliate of the BGN Group and Secures 10-Year Time Charter

Capital Clean Energy Carriers Corp. has agreed to sell a 49% stake in its LNG carrier Amore Mio I to an affiliate of BGN Group via a new joint venture. The joint venture secured a 10-year time charter agreement with BGN INT DMCC, expected to generate revenues up to $485.6 million, enhancing the company's charter portfolio, financial flexibility, an…

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

Mesoblast Acquires Chimeric Antigen Receptor (CAR) Platform Technology for Precision-Enhanced Cell Products

Mesoblast Limited has secured an exclusive worldwide license to innovative chimeric antigen receptor (CAR) technology developed at Mayo Clinic to genetically engineer its mesenchymal stromal cell (MSC) products. The integration aims to significantly improve targeted homing, immunomodulation, and tissue regeneration capabilities of Mesoblast’s FDA-a…